Format

Send to

Choose Destination

Links from PubMed

See comment in PubMed Commons below
EuroIntervention. 2012 Feb;7(10):1181-8. doi: 10.4244/EIJV7I10A189.

One-year outcomes of patients with the zotarolimus-eluting coronary stent: RESOLUTE International Registry.

Author information

1
Heart Center Bad Krozingen, Bad Krozingen, Germany. franz-josef.neumann@herzzentrum.de

Abstract

AIMS:

To provide clinical outcome data from everyday practice for the new generation Resolute zotarolimus-eluting stent (R-ZES).

METHODS AND RESULTS:

Patients were eligible if placement of ≥1 R-ZES was intended. There were no restrictions on clinical indication, number of treated vessels, and lesion characteristics. The primary endpoint was the adjudicated cumulative 1-year incidence of cardiac death and target vessel myocardial infarction. Twenty-five per cent of the patients were randomly selected for monitoring. We recruited 2,349 patients with 3,147 lesions (1.6±1.0 stents per patient); 46.0% of patients had acute coronary syndrome, 30.5% were diabetic, and ≥1 complex criterion for stent placement was present in 67.5% of patients. One-year follow-up was complete in 97.9% of patients. The 1-year incidence of the primary endpoint was 4.3% (95% CI: 3.5% to 5.2%) and for ARC definite and probable stent thrombosis, 0.9% (0.5% to 1.3%). Clinically driven target lesion revascularisation and target lesion failure were 3.4% (2.7% to 4.3%) and 7.0% (6.0% to 8.2%), respectively. These findings were consistent across all lesion and patient subsets analysed. There were no significant differences in outcomes between monitored and unmonitored patients.

CONCLUSIONS:

In everyday practice, the R-ZES performed similarly well as in the RESOLUTE All Comers randomised trial.

PMID:
22334317
DOI:
10.4244/EIJV7I10A189
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Europa Digital & Publishing
    Loading ...
    Support Center